Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 131Thoracic 52Head & Neck 26Genitourinary 14Lymphoid 11Gynecologic 11Other solid neoplasm 9Breast 9Dermatologic 6CNS 6Tumor-Agnostic 3Sarcoma 2Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Neoplasm, Residual 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 414Cytarabine 336fludarabine phosphate 231Rituximab 206Methotrexate 198fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 112Melphalan 110Dexamethasone 109Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Antilymphocyte Serum 91Daunorubicin 90Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 70Prednisone 68Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × tislelizumab × Other hematologic neoplasm × Clear all
NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Beijing 302 Hospital

Phase 2 Recruiting
67 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04541277 2020-09-09

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

Chinese PLA General Hospital

Phase 2 Unknown
55 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡